Governance Classic Home
Supriya Lifescience LtdPharmaceuticalsINE07RO01027Standalone₹905.50+6.75 (+0.75%)Jun-26
Valuation
Market Cap₹7.29K Cr
TTM PE36.77x
Forward PE36.98x
PEG2.66
Book Value₹148.82
P/B6.09x
TTM EPS₹24.65
Fwd EPS₹24.51
TTM Revenue₹872.55 Cr
TTM PAT₹198.38 Cr
TTM EBITDA₹289.81 Cr
TTM EBIT₹258.91 Cr
Last Qtr PAT₹24.04 Cr
Last Qtr EBITDA₹47.46 Cr
Last Qtr EBIT₹38.52 Cr
Profitability
ROE16.56%
ROCE22.00%
TTM NPM22.74%
TTM EBITDA %33.21%
Curr OPM12.49%
Last OPM26.51%
Curr NPM—
Last NPM—
Curr EPS₹2.99
Last EPS₹9.22
Balance sheet
Equity₹16.10 Cr
Reserve₹1.18K Cr
Total Debt₹5.44 Cr
D/E0.00x
Interest %1.54%
Curr Interest₹0.37 Cr
Price / range
Close₹906.30
vs 52W High-16.47%
vs 52W Low+66.10%
MA50—
MA200—
Returns
1D+0.63%
1W+0.18%
1M+12.86%
3M-2.83%
6M+53.83%
1Y+31.78%
2Y+44.97%
3Y+211.71%
5Y—
Diwali+22.67%
Sector peers — Pharmaceuticals
CompanyCloseMkt CapTTM P/EROE
SUNPHARMA1837.30₹4.41L Cr148.173.58%
DIVISLAB9375.00₹2.49L Cr84.6217.55%
TORNTPHARM4840.00₹1.84L Cr78.8025.43%
ZYDUSLIFE1160.00₹1.16L Cr33.2112.96%
CIPLA1394.50₹1.13L Cr36.648.93%
LAURUSLABS1954.00₹1.06L Cr120.9216.46%
AUROPHARMA1734.00₹99.77K Cr38.796.84%
DRREDDY1185.00₹98.91K Cr148.681.75%

Financial Results

Quarterly and yearly P&L · YoY % on Revenue, Total Income, Expenditure, EBITDA, EBIT, PBT, Net Profit and EPS

Standalone

16 lines · 6 periods
MetricJun-26Mar-26Dec-25Sep-25Jun-25FY25-26
Revenue189.75+30.8%276.53206.44199.83145.07827.88
Other Income2.653.482.612.732.6711.49
Total Income192.40+30.2%280.01209.05202.56147.75839.36
Interest0.370.470.490.420.511.89
Expenditure-151.60-51.1%-187.88-141.67-134.24-100.34-564.13
PBDT000000
EBITDA47.46-8.2%97.6272.0872.6551.69294.05
Depreciation-8.94-8.50-6.82-6.64-6.45-28.41
EBIT38.52-14.9%89.1265.2666.0145.24265.64
PBT40.79-14.0%92.1366.9268.3247.41274.78
Tax-16.75-17.90-17.25-17.89-12.62-65.66
Equity16.1016.1016.10016.1016.10
OPM21.2032.9032.0134.1932.0932.74
Net Profit24.04-30.9%74.2349.6850.4334.79209.12
NPM12.4926.5123.7625.2323.5524.91
EPS2.999.226.176.27025.98

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 4 years
MetricFY 25-26FY 24-25FY 23-24FY 22-23
Revenue827.88+18.9%696.49+22.1%570.37+23.7%460.94
Other Income11.499.8210.649.49
Total Income839.36+18.8%706.30+21.6%581.01+23.5%470.43
Expenditure-564.13-23.2%-457.82-10.2%-415.32-19.7%-346.94
Interest-1.89-1.69-2.11-3.08
PBDT0000
EBITDA294.05+12.7%260.80+50.8%172.97+34.2%128.90
Depreciation-28.41-20.44-15.81-11.82
EBIT265.64+10.5%240.36+52.9%157.16+34.2%117.08
PBT274.78+10.6%248.48+50.0%165.69+34.2%123.49
Tax-65.66-60.52-46.58-33.63
Equity16.1016.1000
OPM (%)32.7435.1829.0026.00
Net Profit209.12+11.3%187.96+57.8%119.11+32.6%89.86
NPM (%)24.9126.6121.0019.00
EPS (Rs)25.98+11.3%23.35+57.8%14.80+32.6%11.16
CEPS25.9823.3514.8011.16

Consolidated

16 lines · 1 periods
MetricFY25-26
Revenue827.88
Other Income11.49
Total Income839.36
Interest1.89
Expenditure-564.13
PBDT0
EBITDA294.05
Depreciation-28.41
EBIT265.64
PBT274.78
Tax-65.66
Equity16.10
OPM32.74
Net Profit209.12
NPM24.91
EPS25.98

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 2 years
MetricFY 25-26FY 24-25
Revenue827.88+18.9%696.49
Other Income11.499.82
Total Income839.36+18.8%706.30
Expenditure-564.13-23.2%-457.82
Interest-1.89-1.69
PBDT00
EBITDA294.05+12.7%260.80
Depreciation-28.41-20.44
EBIT265.64+10.5%240.36
PBT274.78+10.6%248.48
Tax-65.66-60.52
Equity16.1016.10
OPM (%)32.7435.18
Net Profit209.12+11.3%187.96
NPM (%)24.9126.61
EPS (Rs)25.98+11.3%23.35
CEPS25.9823.35

Corporate Actions

Dividends, bonus issues, and stock splits

Dividend

3
YearTypeAmountEx-Date
2025Final Dividend104 Sep 2025
2024Final Dividend0.820 Sep 2024
2023Final Dividend0.615 Sep 2023

Bonus

0

No bonus history.

Split

0

No split history.

Loading company dashboard...
Fetching ratios, charts, and peers